Rosuvastatin Effectively Reduces Triglycerides in a Dose-Dependent Manner
Rosuvastatin significantly reduces triglyceride levels by approximately 10-43% depending on dose and baseline triglyceride levels, with the greatest reductions seen in patients with hypertriglyceridemia. 1
Magnitude of Triglyceride Reduction
The FDA-approved labeling demonstrates clear triglyceride-lowering effects across the rosuvastatin dose range:
- In hyperlipidemia patients: Rosuvastatin 5-40 mg reduced triglycerides by 10-28% over 6 weeks 1
- In hypertriglyceridemia patients (baseline TG 273-817 mg/dL): Reductions ranged from 21% (5 mg) to 43% (40 mg) 1
- In primary dysbetalipoproteinemia: 10 mg reduced TG by 40%, while 20 mg reduced TG by 43% 1
The triglyceride-lowering effect appears within 2 weeks and is maintained with continued therapy 2.
Clinical Context and Guidelines
While rosuvastatin reduces triglycerides, statins are not primarily triglyceride-lowering drugs—they are first-line therapy for ASCVD risk reduction in patients with elevated triglycerides 3. The 2021 ACC Expert Consensus emphasizes that in patients aged 40-75 years with mild to moderate hypertriglyceridemia (150-499 mg/dL), statins remain the initial pharmacotherapy choice because they reduce cardiovascular events 3.
Persistent hypertriglyceridemia ≥175 mg/dL is considered an ASCVD risk-enhancing factor that supports initiation or intensification of high-intensity statin therapy 3. The greater the LDL-C lowering achieved by a statin, the greater the triglyceride reduction due to a relatively constant LDL-C/triglyceride-lowering ratio 3.
Dose Considerations
In Japanese hypertriglyceridemic patients, rosuvastatin 5-20 mg showed no clear dose-response for triglyceride lowering (30-32% reduction across doses), though dose-related improvements occurred in other lipid parameters 2. However, FDA data in broader populations demonstrate greater TG reductions with higher doses, particularly in severe hypertriglyceridemia 1.
Additional Lipid Effects
Beyond triglycerides, rosuvastatin produces comprehensive lipid improvements:
- LDL-C reductions: 45-63% (5-40 mg doses) 1
- Non-HDL-C reductions: 44-60% 1
- HDL-C increases: 8-14% 1
- ApoB reductions: 38-54% 1
Important Caveats
Rosuvastatin is not indicated as primary therapy for severe hypertriglyceridemia (≥500 mg/dL), where the goal is pancreatitis prevention rather than ASCVD risk reduction 3. In these patients, triglyceride-specific therapies (fibrates, high-dose omega-3 fatty acids, dietary fat restriction) are prioritized.
Dose adjustments are required in Asian patients (start at 5 mg), patients with severe renal insufficiency (CKD stage IV), and those on cyclosporine or protease inhibitors due to higher drug exposure 4.
The combination of rosuvastatin with fenofibrate produces greater triglyceride reductions (approximately 45%) compared to rosuvastatin monotherapy, though rosuvastatin alone more potently reduces LDL-C and non-HDL-C 5.